(0) - Day 28 full results from the SAVE-MORE study show early treatment with anakinra plus SOC (standard of care) reduced mortality by 55% and reduced average time until ICU (intensive care unit) discharge by four days - Day 28 full results from the SAVE-MORE study show early treatment with anakinra plus SOC (standard of care) reduced mortality by 55% and reduced average time until ICU (intensive care unit) discharge by four days - In patients treated with anakinra plus SOC, overall clinical status improved by 64% compared to those treated with SOC alone - The SAVE-MORE trial, conducted by the Hellenic Institute for the Study of Sepsis, is the first large, pivotal randomised controlled trial to specifically evaluate a target patient population with COVID-19 at risk of progressing and demonstrating the benefit of earlier intervention with anakinra for the prevention of disease progression and reduced risk of mortality